[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Not Op Cue [@NotOpCue](/creator/twitter/NotOpCue) on x 176.5K followers Created: 2025-03-20 22:27:30 UTC 💉⚠️💉⚠️💉99M Vaxxed People Studied: Multiple Significant Safety Signals Exceeded Yet COVID Bioweapon Injections Are Still Being Administered Published electronically on February 12, 2024 was the observational study, "COVID-19 Vaccines And Adverse Events Of Special Interest: A Multinational Global Vaccine Data Network (GVDN) Cohort Study Of XX Million Vaccinated Individuals." Brought to you by the Global COVID Vaccine Safety (GCoVS) Project (established in 2021 by the Global Vaccine Data Network™ a.k.a. GVDN®) which facilitates comprehensive assessments of vaccine safety. This study aimed to evaluate the risk of adverse events of special interest (AESI) following COVID-19 vaccination from XX sites across X countries. There were XX million individuals (99,068,901) included in this study and X types of COVID-19 bioweapon injections considered including @Pfizer / @BioNTech_Group (183,559,462 doses of BNT162b2), @moderna_tx (36,178,442 doses of mRNA-1273) and @AstraZeneca (23,093,399 doses of ChAdOx1). Risks were assessed using observed versus expected (OE) ratios of adverse events and the following were only the statistically significant safety signals (red) yet they are still being administered: ⚠️249% OE For Guillain-Barré Syndrome (GBS) From 1st Dose ChAdOx1 ⚠️323% OE For Cerebral Venous Sinus Thrombosis (CVST) From 1st Dose ChAdOx1 ⚠️378% OE For Acute Disseminated Encephalomyelitis (ADEM) From 1st Dose mRNA-1273 ⚠️348% OE For Myocarditis (MYO) From 1st Dose mRNA-1273 ⚠️174% OE For Pericarditis (PER) From 1st Dose mRNA-1273 ⚠️278% OE For Myocarditis (MYO) From 1st Dose BNT162b2 ⚠️286% OE For Myocarditis (MYO) From 2nd Dose BNT162b2 ⚠️610% OE For Myocarditis (MYO) From 2nd Dose mRNA-1273 ⚠️91% OE For Pericarditis (PER) From 3rd Dose ChAdOx1 ⚠️209% OE For Myocarditis (MYO) From 3rd Dose BNT162b2 ⚠️201% OE For Myocarditis (MYO) From 3rd Dose mRNA-1273 ⚠️264% OE For Pericarditis (PER) From 4th Dose mRNA-1273 cc: @SecKennedy @RobertKennedyJr 🔗 Full PDF Hosted On @ElsevierConnect: 🔗 Full Study Hosted On @NLM_NIH: ↙️↙️Read & Share The Full Article↘️↘️ 🔍 "The Adverse Effects of Experimental Messenger RNA (mRNA) "Vaccines" a.k.a. Injections For COVID-19" 💊 💊  XXXXXXX engagements  **Related Topics** [events](/topic/events) [signals](/topic/signals) [op](/topic/op) [Post Link](https://x.com/NotOpCue/status/1902849508171550907)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Not Op Cue @NotOpCue on x 176.5K followers
Created: 2025-03-20 22:27:30 UTC
💉⚠️💉⚠️💉99M Vaxxed People Studied: Multiple Significant Safety Signals Exceeded Yet COVID Bioweapon Injections Are Still Being Administered
Published electronically on February 12, 2024 was the observational study, "COVID-19 Vaccines And Adverse Events Of Special Interest: A Multinational Global Vaccine Data Network (GVDN) Cohort Study Of XX Million Vaccinated Individuals." Brought to you by the Global COVID Vaccine Safety (GCoVS) Project (established in 2021 by the Global Vaccine Data Network™ a.k.a. GVDN®) which facilitates comprehensive assessments of vaccine safety.
This study aimed to evaluate the risk of adverse events of special interest (AESI) following COVID-19 vaccination from XX sites across X countries. There were XX million individuals (99,068,901) included in this study and X types of COVID-19 bioweapon injections considered including @Pfizer / @BioNTech_Group (183,559,462 doses of BNT162b2), @moderna_tx (36,178,442 doses of mRNA-1273) and @AstraZeneca (23,093,399 doses of ChAdOx1).
Risks were assessed using observed versus expected (OE) ratios of adverse events and the following were only the statistically significant safety signals (red) yet they are still being administered:
⚠️249% OE For Guillain-Barré Syndrome (GBS) From 1st Dose ChAdOx1 ⚠️323% OE For Cerebral Venous Sinus Thrombosis (CVST) From 1st Dose ChAdOx1 ⚠️378% OE For Acute Disseminated Encephalomyelitis (ADEM) From 1st Dose mRNA-1273 ⚠️348% OE For Myocarditis (MYO) From 1st Dose mRNA-1273 ⚠️174% OE For Pericarditis (PER) From 1st Dose mRNA-1273 ⚠️278% OE For Myocarditis (MYO) From 1st Dose BNT162b2 ⚠️286% OE For Myocarditis (MYO) From 2nd Dose BNT162b2 ⚠️610% OE For Myocarditis (MYO) From 2nd Dose mRNA-1273 ⚠️91% OE For Pericarditis (PER) From 3rd Dose ChAdOx1 ⚠️209% OE For Myocarditis (MYO) From 3rd Dose BNT162b2 ⚠️201% OE For Myocarditis (MYO) From 3rd Dose mRNA-1273 ⚠️264% OE For Pericarditis (PER) From 4th Dose mRNA-1273
cc: @SecKennedy @RobertKennedyJr
🔗 Full PDF Hosted On @ElsevierConnect:
🔗 Full Study Hosted On @NLM_NIH:
↙️↙️Read & Share The Full Article↘️↘️ 🔍 "The Adverse Effects of Experimental Messenger RNA (mRNA) "Vaccines" a.k.a. Injections For COVID-19" 💊 💊
XXXXXXX engagements
